Heron Therapeutics | HRTX - Debt


Heron Therapeutics reported $149.65M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
ALKERMES USD 71.6M 1.08M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Eisai JPY 236.67B 49.14B Sep/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.89M 163.33M Dec/2025
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 372.19M 4.53M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Surmodics USD 29.55M 111K Sep/2024
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Veracyte USD 40.45M 10.19M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025